Strong pipeline and new product launches are the key positives. Additionally, smooth operation ahead of VAI from US FDA for the company's facilities should support topline growth over the medium term. Hence, we upgrade our rating to BUY on the stock with a revised target price of Rs. 4,344 based on 23x FY22E adj. EPS....